An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration
Anti-vascular endothelial growth factor agents have been widely used to treat several eye diseases including age-related macular degeneration (AMD). An approach to maximize the local concentration of drug at the target site and minimize systemic exposure is to be sought. Sunitinib malate, a multiple receptor tyrosine kinase inhibitor was encapsulated in poly(lactic-co-glycolic acid) nanoparticles to impart sustained release. The residence time in vitreal fluid was further increased by incorporating nanoparticles in thermo-reversible gel. Nanoparticles were characterized using TEM, DSC, FTIR, and in vitro drug release profile. The cytotoxicity of the formulation was assessed on ARPE-19 cells using the MTT assay. The cellular uptake, wound scratch assay, and VEGF expression levels were determined in in vitro settings. The optimized formulation had a particle size of 164.5 nm and zeta potential of − 18.27 mV. The entrapment efficiency of 72.0% ± 3.5% and percent drug loading of 9.1 ± 0.7% were achieved. The viability of ARPE-19 cells was greater than 90% for gel loaded, as such and blank nanoparticles at 10 μM and 20 μM concentration tested, whereas for drug solution viability was found to be 83% and 71% respectively at above concentration. The cell viability results suggest the compatibility of the developed formulation. Evaluation of cellular uptake, wound scratch assay, and VEGF expression levels for the developed formulations indicated that the formulation had higher uptake, superior anti-angiogenic potential, and prolonged inhibition of VEGF activity compared with drug solution. The results showed successful development of sunitinib-loaded nanoparticle-based thermo-reversible gel which may be used for the treatment of neovascular AMD.
KEY WORDSsunitinib PLGA nanoparticles sustained release ocular delivery intravitreal VEGF
The authors would like to acknowledge the Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi, University, MS, USA, for providing start-up support to Dr. Chougule’s lab. The authors would also like to acknowledge the Lisa Muma Weitz Laboratory for Advanced Microscopy and Cell Imaging, USF Health, University of South Florida, Tampa, FL, USA, for providing facility for microscopy and imaging and Department of Chemistry, College of Arts and Science, University of South Florida, Tampa, FL, USA, for providing facility for DSC study.
The authors would like to thank High Tech Corridor Matching Grant Program (FHT 17-20) with Param Bhakti Healthcare and Research for providing necessary funding for this work.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.Shang Q, Zhai J, Tian R, Zheng T, Zhang X, Liang X, et al. Fabrication, characterization, and controlled release of eprinomectin from injectable mesoporous PLGA microspheres. RSC Adv. 2015;5(92):75025–32.Google Scholar
- 3.Hoare TR, Kohane DS. Hydrogels in drug delivery: progress and challenges. Polymer. 2008;49(8):1993–2007.Google Scholar
- 10.Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser. Available from: https://ClinicalTrials.gov/show/NCT03590444. Accessed 23 May 2018.
- 11.Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR). Available from: https://ClinicalTrials.gov/show/NCT03452657. Accessed 23 May 2018.
- 12.Maguire MG, Martin DF, Ying G-S, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The Comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–61.PubMedGoogle Scholar
- 13.Pieramici DJ, Lu N, Stoilov IJIO, Science V. Diabetic retinopathy outcomes with anti-VEGF treatments: clinical experience in randomized clinical trials. 2015;56(7):1775.Google Scholar
- 20.Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed Nanotechnol Biol Med. 2010;6(5):662–71.Google Scholar
- 23.Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. J Drug Delivery Sci Technol. 2018;45:334–45.Google Scholar
- 24.Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Adv. 2016;6(112):110951–63.Google Scholar
- 28.Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro</em> efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065.Google Scholar
- 32.Kathleen H, Shannon JK, Iqbal MT, Yashwant P, Vijaykumar S. Utilization of apatinib-loaded nanoparticles for the treatment of ocular neovascularization. Curr Drug Deliv. 2019;16(2):153–63.Google Scholar
- 33.Pirooznia N, Hasannia S, Lotfi AS, Ghanei M. Encapsulation of alpha-1 antitrypsin in PLGA nanoparticles: in vitro characterization as an effective aerosol formulation in pulmonary diseases. J Nanobiotechnol. 2012;10:20.Google Scholar
- 43.Alshetaili AS, Anwer MK, Alshahrani SM, Alalaiwe A, Alsulays BB, Ansari MJ, et al. Characteristics and anticancer properties of sunitinib malate-loaded poly-lactic-co-glycolic acid nanoparticles against human colon cancer HT-29 cells lines. Tropical Journal of Pharmaceutical Research. 2018;17(7):1263−9.Google Scholar
- 44.Sadat SM, Jahan ST, Haddadi AJ. Effects of size and surface charge of polymeric nanoparticles on in vitro and in vivo applications. Nanobiotechnology. 2016;7(02):91.Google Scholar
- 45.Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. Chapter-1: In-vitro and in-vivo tools in emerging drug delivery scenario: Challenges and Updates. In-vitro and In-vivo tools in drug delivery research for optimum clinical outcomes; 2018; 1st edition; Editors: Misra A and Shahiwala A. CRC press, Boca Raton. 8–1. https://doi.org/10.1201/b2244.
- 48.Senger DR, Davis GE. Cold Spring Harbor perspectives in biology. Angiogenesis. n.d.;3(8):a005090-a.Google Scholar